Sign In
Buy HOWL
$0.362
-0.0084 (-2.27%)
At Close: Jun 23, 2026
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
01:01pm, Monday, 15'th Apr 2024
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
WTX-518, a conditionally activated IL-18 INDUKINE TM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
04:57pm, Thursday, 04'th Apr 2024
Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bow
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
10:55am, Tuesday, 12'th Mar 2024
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend i
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
09:46am, Thursday, 07'th Mar 2024
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Thursday, 07'th Mar 2024
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 –
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
08:00am, Wednesday, 06'th Mar 2024
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developmen
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
04:30pm, Tuesday, 05'th Mar 2024
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developmen
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
07:00am, Monday, 08'th Jan 2024
- Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 -
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
04:05pm, Thursday, 04'th Jan 2024
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines
07:09pm, Thursday, 28'th Dec 2023
HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
07:00am, Wednesday, 22'nd Nov 2023
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
04:25pm, Tuesday, 14'th Nov 2023
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity
Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days
05:14pm, Monday, 06'th Nov 2023
Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of I
